Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation

Inclusion Criteria: * Women between 35 and 50 years of age (inclusive) * Women who will be scheduled to undergo an RRSO or RRs * Women who will have at least one fallopian tube removed for risk-reducing reasons (with or without removal of ovar(ies)) * Women who are willing to have a Mirena® IUD inserted at least prior to risk-reducing surgery or who already have the Mirena® in place * Women using non-hormonal forms of contraception (Note: If a copper IUD is being used, the IUD must be removed prior to or at time of Mirena insertion.) Exclusion Criteria: * Any medical contraindication to use of a Mirena® IUD, including: * Pregnancy (a pregnancy test is required prior to study entry) * Known uterine anomaly that distorts the shape of the uterine cavity * Acute pelvic inflammatory disease * Postpartum endometritis or endometrial infection * Known or suspected uterine or cervical neoplasia * Known history or suspected breast cancer or other progestin-sensitive cancer * Uterine bleeding of unknown etiology. * Untreated acute cervicitis, vaginitis, or other lower genital tract infections * Acute liver disease or liver tumor (benign or malignant) * Use of tamoxifen, raloxifene, or chemotherapy within the previous 6 months * Positive pregnancy test * Breastfeeding * Use of a copper IUD if the patient is not willing to have it removed prior to surgery and replaced with a Mirena® IUD